Dofetilide: A new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/atrial flutter

Drugs of Today

Volumn 36, Issue 11, 2000, Pages 759-771

  Lenz, T L ^a   Hilleman, D E ^a  

^a CREIGHTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ASTEMIZOLE; CALCIUM; CISAPRIDE; CYTOCHROME P450 3A4; DIGOXIN; DOFETILIDE; ERYTHROMYCIN; FLECAINIDE; HALOPERIDOL; NORADRENALIN; POTASSIUM; SOTALOL; TRICYCLIC ANTIDEPRESSANT AGENT; WARFARIN;

CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; ELECTROCARDIOGRAPHY; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART VENTRICLE TACHYCARDIA; HUMAN; NONHUMAN; REVIEW; THORAX PAIN; TORSADE DES POINTES; VERTIGO;

EID: 0034533650     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2000.36.11.601530     Document Type: Review

References (48)

1. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications
2. An aggressive treatment strategy for atrial fibrillation
3. Atrial fibrillation follow-up investigation of rhythm management - The AFFIRM study design. The Planning and Steering Committees of the AFFIRM Study for the NHLBI AFFIRM Investigators
4. The medical management of atrial fibrillation
5. Antiarrhythmic drug therapy in the treatment of atrial fibrillation
6. Atrial fibrillation: Maintenance of sinus rhythm versus rate control
7. Atrial fibrillation: Restoration and maintenance of sinus rhythm and indications for anticoagulation therapy
8. Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide
9. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension
10. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmic Suppression Trial (CAST) Investigators
11. Superiority of ibutilide over DL-Sotalol in converting atrial flutter and fibrillation
12. Spontaneous conversion of maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation
13. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF STAT Investigators
14. Side effects of amiodarone
15. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled study
16. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion
17. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias: A meta-analysis
18. Acute effect of disopyramide on atrial fibrillation in the Wolff-Parkinson-White syndrome
19. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized controlled trials
20. UK-68,798: A novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells
21. Focus on dofetilide. A selective class III antiarrhythmic agent
22. New class III antiarrhythmic drugs
23. k blocking drug, UK-68, 798: Potent in guinea pig but no effect in rat myocardium
24. kr) in AT-1 cells. Concentration-, time-, voltage- and use-dependent effects
25. A dose-ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteers
26. Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug
27. Pharmacodynamics and pharmacokinetics of the class III antiarrhythmic agent dofetilide (UK-68,798) in humans
28. Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia
29. Intravenous dofetilide, a class III antiarrhyth mic agent, for the termination of sustained atrial fibrillation or flutter
30. Pharmacokinetics and pharmacodynamics of dofetilide: Daily versus intermittent dosing
31. Cardiac electrophysiologic and inotropic actions of new and potent methanesulfonanilide class III antiarrhythmic agents in anesthetized dogs
32. Electropharmacology of dofetilide, a new class III agent, in anaesthetised dogs
33. Contrasting effects of intravenous dofetilide and amiodarone on cardiac sympathetic drive in patients with congestive heart failure
34. A randomized, double-blind, placebo-controlled dose-ranging study of intravenous UK-68,798 (dofetilide) in patients with inducible sustained ventricular tachyarrhythmias
35. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris
36. Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris
37. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter
38. Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class IC drug
39. Oral dofetilide for conversion of patients with chronic atrial fibrillation or atrial flutter to normal sinus rhythm: A multicenter study
40. DIAMOND (Danish Investigations of Arrhythmia and Mortality on Dofetilide)
41. Dofetilide in the treatment of atrial fibrillation in patients with impaired left ventricular function: Atrial fibrillation in the DIAMOND study
42. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
43. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian MultiCenter Evaluative Research on Atrial Fibrillation Dofetilide) Study
44. Effect of dofetilide on survival in patients with supraventricular tachycardia
45. Dofetilide, a novel class III antiarrhythmic agent
46. The effect of dofetilide on pharmacodynamics of warfarin and pharmacokinetics of digoxin